All In Biotech

Free tool

FAERS Monitor: Risperdal Consta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021346 or its brand name (Risperdal Consta, Risperidone). Reports on generic versions are filed under their own applications.

Reports

75,399

Serious

55,531

74% of reports

Hospitalization

26,510

Death reported

6,676

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • gynaecomastia10,050
  • off label use6,177
  • drug ineffective5,775
  • weight increased4,872
  • drug interaction3,355
  • abnormal weight gain3,128
  • product use in unapproved indication3,031
  • emotional disorder3,005
  • condition aggravated2,577
  • somnolence2,450
  • toxicity to various agents2,312
  • extrapyramidal disorder2,244
  • anxiety2,080
  • psychotic disorder2,039
  • emotional distress2,037

Reports by year received

View as table
YearReports
2004541
2005678
2006935
2007851
20081,012
20091,662
20101,654
20112,063
20122,326
20131,886
20142,264
20157,746
20166,152
20177,820
20185,097
20195,327
20204,534
20214,078
20224,181
20233,896
20243,917
20253,858
20262,920

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,978,760 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
gynaecomastiaSignal10,050133.7130.7895,172
abnormal weight gainSignal3,12894.290.5215,576
emotional disorderSignal3,00530.028.976,182
extrapyramidal disorderSignal2,24427.626.552,392
psychotic disorderSignal2,03920.619.735,467
weight increasedSignal4,8726.26.020,918
drug interactionSignal3,3556.05.813,799
emotional distressSignal2,0374.84.65,973
toxicity to various agentsSignal2,3123.93.74,876
product use in unapproved indicationSignal3,0313.43.35,245
somnolenceSignal2,4503.43.34,190
condition aggravatedSignal2,5772.42.32,065
anxietySignal2,0802.02.01,119
off label use6,1772.01.93,078
drug ineffective5,7751.21.2250

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.